Real-World Skin Clearance and Quality of Life with risankizumab in Patients with Psoriasis with Moderate Skin Involvement and Those Eligible for Systemic Therapy Per International Psoriasis Council Classification

By afschroeder • July 2, 2025

Strober B, Patel M, Kaldas MI, St John G, Photowala H, Sima AP, Eckmann T, Beeghly A, Armstrong A. Real-World Skin Clearance and Quality of Life with risankizumab in Patients with Psoriasis with Moderate Skin Involvement and Those Eligible for Systemic Therapy Per International Psoriasis Council Classification. Dermatol Ther (Heidelb). 2025 Jul 2. doi: 10.1007/s13555-025-01474-3. Epub ahead of print. PMID: 40593269.

Tags: CorEvitas Psoriasis Registry, Dermatology, International Psoriasis Council disease reclassification, National Psoriasis Foundation treat-to-target goals, patient-reported outcomes, psoriasis, Publications, real-world, risankizumab, Skin clearance, Systemic-eligible

GLP-1RAs and cardiovascular risk reduction in hidradenitis suppurativa: A real-world cohort study

Chou PP, Jeong C, Ma E, Roberts AM, Katz A, Nong Y, Yan MJ, Johnsen N, Armstrong AW. GLP-1RAs and cardiovascular risk reduction in hidradenitis[...]

Tapinarof Cream for Adults and Children with Atopic Dermatitis-Efficacy by Race and Fitzpatrick Skin Type in Two Phase 3 Randomized Clinical Trials

Alexis AF, Kircik L, Chovatiya R, Rice ZP, Soong W, Bhutani T, Brown PM, Piscitelli SC, Rubenstein DS, Tallman AM, Armstrong AW. Tapinarof Cream for[...]

Emergency versus Outpatient Care for Pediatric Atopic Dermatitis: A Population-Based Study of Sociodemographic Factors and Health Care Utilization

Yamamoto RK, Tolson HC, Hao A, Kikuchi R, Sadrolashrafi K, Guo L, Bilimoria SN, Yee D, Armstrong AW. Emergency versus Outpatient Care for Pediatric Atopic[...]